Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300 mg doses of HER-096 or placebo twice weekly over a four-week ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

Results from the Phase II COLLECTiVE202 trial (NCT05370885) demonstrated a statistically significant difference between VE202 ...

H-D Feminine Health, announces it has initiated the first randomized, placebo-controlled, double-blinded Phase 3 clinical trial cleared to proceed by the U.S. Food and Drug Administration (FDA) to ...

In this Q&A, Rohit Nambisan, CEO of Lokavant, and Jonathan Crowther, head of predictive analytics, Pfizer, explore how AI is ...

Shore Capital Partners has formed PhaseWell Research, a Nashville-based clinical research site company. No financial terms were disclosed. In conjunction with the formation, Carsten Bick has been ...

Clinical trial updates in cancer care include a remote study in small cell lung cancer and new findings in ovarian, solid ...

Pelage’s PP405, a first-in-class regenerative treatment, reactivates dormant stem cells to regrow hair. Phase 2a shows early, significant results.

Management reiterated the expectation that Elfabrio royalties will exceed $100 million by 2030, based on a projected 15% to 20% market share of the Fabry disease market.

A Phase 1 human clinical trial to treat chronic spinal cord injury, the first of its kind in the world, has commenced to test ...

HHS' decision "could stagnate research that has the potential to save millions of lives," writes Simon Williams.